Langer-backed Sigilon sets sail with $23M and new ‘living’ cell therapy tech
While Flagship Pioneering was unwrapping a huge $120 million round for Rubius this morning, the busy venture group also launched a biotech on a mission to create a new type of encapsulated cell therapy.
Turning to two scientific founders — MIT’s Daniel Anderson and the prolific Robert Langer — the discovery group at Flagship has been working on permeable biomaterials that are designed to implant cells in tissue to deliver proteins in a sustained fashion, without triggering fibrosis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.